Hims & Hers: FDA Warning, Stock Dip, and New Bets
Update: 2025-09-16
Description
Hims & Hers stock plunges after an FDA warning! The agency called out the telehealth company for false or misleading claims about its compounded semaglutide, suggesting they mimic Ozempic and Wegovy. Is this a short-term stumble or a sign of deeper trouble as Hims & Hers doubles down on men's health to offset slowing weight-loss drug sales? Find out how the company plans to respond and whether analysts are still betting on a comeback.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
